158 related articles for article (PubMed ID: 29449427)
1. Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils.
Pedersen F; Waschki B; Marwitz S; Goldmann T; Kirsten A; Malmgren A; Rabe KF; Uddin M; Watz H
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29449427
[No Abstract] [Full Text] [Related]
2. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
[TBL] [Abstract][Full Text] [Related]
3. The double-edged sword of neutrophilic inflammation in bronchiectasis.
Martínez-García MÁ; Sánchez CP; Moreno RM
Eur Respir J; 2015 Oct; 46(4):898-900. PubMed ID: 26424521
[No Abstract] [Full Text] [Related]
4. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
[TBL] [Abstract][Full Text] [Related]
5. NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma.
Uddin M; Watz H; Malmgren A; Pedersen F
Front Immunol; 2019; 10():47. PubMed ID: 30804927
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients.
Pedersen F; Marwitz S; Holz O; Kirsten A; Bahmer T; Waschki B; Magnussen H; Rabe KF; Goldmann T; Uddin M; Watz H
Respir Med; 2015 Oct; 109(10):1360-2. PubMed ID: 26321138
[TBL] [Abstract][Full Text] [Related]
7. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.
Watz H; Uddin M; Pedersen F; Kirsten A; Goldmann T; Stellmacher F; Groth E; Larsson B; Böttcher G; Malmgren A; Kraan M; Rabe KF
Pulm Pharmacol Ther; 2017 Aug; 45():121-123. PubMed ID: 28549850
[No Abstract] [Full Text] [Related]
8. Evidence of eosinophil extracellular trap cell death in COPD: does it represent the trigger that switches on the disease?
Uribe Echevarría L; Leimgruber C; García González J; Nevado A; Álvarez R; García LN; Quintar AA; Maldonado CA
Int J Chron Obstruct Pulmon Dis; 2017; 12():885-896. PubMed ID: 28352169
[TBL] [Abstract][Full Text] [Related]
9. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation.
Grabcanovic-Musija F; Obermayer A; Stoiber W; Krautgartner WD; Steinbacher P; Winterberg N; Bathke AC; Klappacher M; Studnicka M
Respir Res; 2015 May; 16(1):59. PubMed ID: 25994149
[TBL] [Abstract][Full Text] [Related]
11. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways.
Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B
J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552
[TBL] [Abstract][Full Text] [Related]
12. CXCR2 Inhibition - a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial.
Joseph JP; Reyes E; Guzman J; O'Doherty J; McConkey H; Arri S; Kakkar R; Beckley N; Douiri A; Barrington SF; Redwood SR; Ferro A
Trials; 2017 Oct; 18(1):473. PubMed ID: 29020983
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
[TBL] [Abstract][Full Text] [Related]
14. Phospholipase D2 drives mortality in sepsis by inhibiting neutrophil extracellular trap formation and down-regulating CXCR2.
Lee SK; Kim SD; Kook M; Lee HY; Ghim J; Choi Y; Zabel BA; Ryu SH; Bae YS
J Exp Med; 2015 Aug; 212(9):1381-90. PubMed ID: 26282875
[TBL] [Abstract][Full Text] [Related]
15. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.
Lazaar AL; Miller BE; Tabberer M; Yonchuk J; Leidy N; Ambery C; Bloomer J; Watz H; Tal-Singer R
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139779
[No Abstract] [Full Text] [Related]
16. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of WO2012080456 and WO2012080457; Boheringer Ingleheim's first CXCR2 antagonists.
Norman P
Expert Opin Ther Pat; 2013 Mar; 23(3):383-8. PubMed ID: 23321068
[TBL] [Abstract][Full Text] [Related]
18. Role of Neutrophil Extracellular Traps in Asthma and Chronic Obstructive Pulmonary Disease.
Liu T; Wang FP; Wang G; Mao H
Chin Med J (Engl); 2017 Mar; 130(6):730-736. PubMed ID: 28303858
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
Leaker BR; Barnes PJ; O'Connor B
Respir Res; 2013 Dec; 14(1):137. PubMed ID: 24341382
[TBL] [Abstract][Full Text] [Related]
20. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
